Cantor Fitzgerald Analysts Raise Earnings Estimates for CMPS

COMPASS Pathways plc (NASDAQ:CMPS - Free Report) - Investment analysts at Cantor Fitzgerald increased their FY2025 earnings per share (EPS) estimates for COMPASS Pathways in a note issued to investors on Wednesday, May 28th. Cantor Fitzgerald analyst C. Duncan now expects that the company will post earnings per share of ($1.00) for the year, up from their prior estimate of ($1.91). Cantor Fitzgerald currently has a "Overweight" rating and a $12.00 target price on the stock. The consensus estimate for COMPASS Pathways' current full-year earnings is ($2.33) per share.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.03.

Other equities analysts also recently issued reports about the company. Canaccord Genuity Group lowered their price objective on COMPASS Pathways from $23.00 to $15.00 and set a "buy" rating for the company in a research report on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and issued a $45.00 price objective on shares of COMPASS Pathways in a research note on Monday, May 12th. Finally, Stifel Nicolaus initiated coverage on shares of COMPASS Pathways in a research note on Thursday, February 27th. They set a "buy" rating and a $11.00 target price for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, COMPASS Pathways presently has a consensus rating of "Buy" and an average price target of $18.83.

COMPASS Pathways Trading Up 6.6%

NASDAQ CMPS traded up $0.29 on Friday, reaching $4.66. The company had a trading volume of 560,815 shares, compared to its average volume of 856,617. The firm has a market cap of $436.00 million, a price-to-earnings ratio of -2.12 and a beta of 2.27. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways has a fifty-two week low of $2.49 and a fifty-two week high of $8.54. The business has a 50 day moving average of $3.59 and a two-hundred day moving average of $3.88.

Institutional Trading of COMPASS Pathways

A number of hedge funds have recently bought and sold shares of CMPS. RTW Investments LP bought a new stake in shares of COMPASS Pathways during the 4th quarter worth $11,714,000. Nantahala Capital Management LLC raised its position in COMPASS Pathways by 182.9% in the first quarter. Nantahala Capital Management LLC now owns 2,829,232 shares of the company's stock worth $8,092,000 after acquiring an additional 1,829,232 shares during the period. Vivo Capital LLC raised its stake in shares of COMPASS Pathways by 109.1% in the first quarter. Vivo Capital LLC now owns 3,362,385 shares of the company's stock valued at $9,616,000 after buying an additional 1,754,385 shares during the period. Altium Capital Management LLC purchased a new stake in COMPASS Pathways in the 4th quarter worth about $5,384,000. Finally, Woodline Partners LP raised its stake in COMPASS Pathways by 279.9% in the 1st quarter. Woodline Partners LP now owns 1,754,856 shares of the company's stock valued at $5,019,000 after acquiring an additional 1,292,927 shares during the period. 46.19% of the stock is currently owned by institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.